Wendell David Associates Inc Abb Vie Inc. Transaction History

Wendell David Associates Inc

$1 Billion
Q1 2025

A detailed history of Wendell David Associates Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Wendell David Associates Inc holds 101,869 shares of ABBV stock, worth $20 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares

101,869

Previous 102,174 0.3%

Holding current value

$20 Million

Previous $18.2 Million 17.56%

% of portfolio

2.13%

Previous 1.8%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 18, 2025	SELL	$169.2 - $216.66 $51,606 - $66,081	-305 Reduced 0.3%	101,869 $21.3 Million
Q4 2024 Jan 17, 2025	SELL	$164.99 - $203.87 $301,436 - $372,470	-1,827 Reduced 1.76%	102,174 $18.2 Million
Q3 2024 Oct 21, 2024	SELL	$163.84 - $199.33 $81,920 - $99,665	-500 Reduced 0.48%	104,001 $20.5 Million
Q2 2024 Jul 22, 2024	BUY	$154.79 - $180.76 $17,336 - $20,245	112 Added 0.11%	104,501 $17.9 Million
Q1 2024 Apr 22, 2024	BUY	$159.82 - $182.1 $14,223 - $16,206	89 Added 0.09%	104,389 $19 Million
Q4 2023 Jan 22, 2024	BUY	$137.6 - $154.97 $141,040 - $158,844	1,025 Added 0.99%	104,300 $16.2 Million
Q3 2023 Oct 20, 2023	BUY	$133.59 - $154.65 $465,026 - $538,336	3,481 Added 3.49%	103,275 $15.4 Million
Q2 2023 Jul 20, 2023	SELL	$132.51 - $164.9 $115,018 - $143,133	-868 Reduced 0.86%	99,794 $13.4 Million
Q1 2023 Apr 19, 2023	SELL	$144.61 - $166.54 $132,028 - $152,051	-913 Reduced 0.9%	100,662 $16 Million
Q4 2022 Jan 17, 2023	SELL	$138.31 - $165.87 $24,895 - $29,856	-180 Reduced 0.18%	101,575 $16.4 Million
Q3 2022 Oct 18, 2022	SELL	$134.21 - $153.93 $86,431 - $99,130	-644 Reduced 0.63%	101,755 $13.7 Million
Q2 2022 Jul 14, 2022	BUY	$137.62 - $174.96 $44,726 - $56,862	325 Added 0.32%	102,399 $15.7 Million
Q1 2022 Apr 22, 2022	SELL	$131.98 - $163.75 $410,853 - $509,753	-3,113 Reduced 2.96%	102,074 $16.5 Million
Q4 2021 Jan 24, 2022	SELL	$107.43 - $135.93 $131,709 - $166,650	-1,226 Reduced 1.15%	105,187 $14.2 Million
Q3 2021 Oct 19, 2021	BUY	$106.4 - $120.78 $182,263 - $206,896	1,713 Added 1.64%	106,413 $11.5 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $569,396 - $634,340	5,412 Added 5.45%	104,700 $11.8 Million
Q1 2021 Apr 20, 2021	BUY	$102.3 - $112.62 $41,943 - $46,174	410 Added 0.41%	99,288 $10.7 Million
Q4 2020 Jan 22, 2021	SELL	$80.49 - $108.67 $380,556 - $513,791	-4,728 Reduced 4.56%	98,878 $10.6 Million
Q3 2020 Oct 20, 2020	SELL	$85.91 - $100.83 $75,944 - $89,133	-884 Reduced 0.85%	103,606 $9.08 Million
Q2 2020 Jul 17, 2020	SELL	$73.37 - $98.18 $16,728 - $22,385	-228 Reduced 0.22%	104,490 $10.3 Million
Q1 2020 Apr 16, 2020	SELL	$64.5 - $97.79 $4,515 - $6,845	-70 Reduced 0.07%	104,718 $7.98 Million
Q4 2019 Jan 17, 2020	SELL	$72.13 - $90.25 $43,278 - $54,150	-600 Reduced 0.57%	104,788 $9.28 Million
Q3 2019 Oct 22, 2019	SELL	$62.98 - $75.72 $171,935 - $206,715	-2,730 Reduced 2.53%	105,388 $7.98 Million
Q2 2019 Jul 16, 2019	SELL	$65.7 - $83.98 $168,520 - $215,408	-2,565 Reduced 2.32%	108,118 $7.86 Million
Q1 2019 Apr 11, 2019	SELL	$77.14 - $90.79 $249,007 - $293,070	-3,228 Reduced 2.83%	110,683 $8.92 Million
Q4 2018 Jan 17, 2019	SELL	$77.85 - $96.01 $176,641 - $217,846	-2,269 Reduced 1.95%	113,911 $10.5 Million
Q2 2018 Jul 16, 2018	BUY	$89.78 - $106.23 $338,919 - $401,018	3,775 Added 3.36%	116,180 $10.8 Million
Q1 2018 Apr 11, 2018	SELL	$92.01 - $123.21 $57,322 - $76,759	-623 Reduced 0.55%	112,405 $10.6 Million
Q4 2017 Jan 16, 2018	SELL	$89.56 - $98.21 $632,741 - $693,853	-7,065 Reduced 5.88%	113,028 $10.9 Million
Q3 2017 Oct 17, 2017	BUY	$69.85 - $89.22 $8.39 Million - $10.7 Million	120,093	120,093 $10.7 Million

Others Institutions Holding ABBV

# of Institutions

4,198

Shares Held

1.29B

Call Options Held

17.1M

Put Options Held

15.1M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $347B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wendell David Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wendell David Associates Inc with notifications on news.

Account

Wendell David Associates Inc Abb Vie Inc. Transaction History